N

Noile-Immune Biotech Inc
TSE:4893

Watchlist Manager
Noile-Immune Biotech Inc
TSE:4893
Watchlist
Price: 202 JPY 3.06% Market Closed
Market Cap: 8.7B JPY

Noile-Immune Biotech Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Noile-Immune Biotech Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
N
Noile-Immune Biotech Inc
TSE:4893
Long-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Long-Term Debt
ÂĄ1.6B
CAGR 3-Years
102%
CAGR 5-Years
5%
CAGR 10-Years
12%
PeptiDream Inc
TSE:4587
Long-Term Debt
ÂĄ17.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
Long-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharma Foods International Co Ltd
TSE:2929
Long-Term Debt
ÂĄ1.1B
CAGR 3-Years
-25%
CAGR 5-Years
-10%
CAGR 10-Years
116%
C
Cuorips Inc
TSE:4894
Long-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Noile-Immune Biotech Inc
Glance View

Market Cap
8.7B JPY
Industry
Biotechnology

Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.

Noile-Immune Biotech Inc Intrinsic Value
HIDDEN
Show

See Also

What is Noile-Immune Biotech Inc's Long-Term Debt?
Long-Term Debt
0 JPY

Based on the financial report for Dec 31, 2023, Noile-Immune Biotech Inc's Long-Term Debt amounts to 0 JPY.

Back to Top